Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We are confident in our ability to make continued improvement in Medicare Advantage pricing and in the shift of our Medicare Advantage admissions to these improved contracts |
| Cost per day improved sequentially to $76 after stabilizing at $77 for the prior 3 quarters as the elimination of nursing contract labor and increased census helped gain leverage against the fixed cost associated with the case management staffing model |
| Payer innovation success, including the execution of another new national contract, continued success with our people strategy and strong performance in quality outcomes are but a few of our high points for the end of 2023 and our start to 2024 |
| Our strongest factor in negotiating with payers and conveners and in creating strong referral relationships remains our 30-day hospital readmission rate that is 20.5% better than the national average |
| On the volume as it relates to the contracts that we've signed, I do think that there's an ability to grow the volume |
| So as you mentioned, going from 5% to 25%, we felt was really good improvement this year |
| We are proud that our team provides hospice visits in the last phase of life 53.2% better than the national average |
| Obviously, it's jumped from, I think, 5% to 25% a year, which is pretty good success |
| And so I think we're entering referral sources today very differently with a much longer list, and that should help us to be able to, frankly, grow all volumes but particularly focused on those in the payer innovation contract and fee-for-service Medicare |
| With our strong quality metrics and our increased list of the payers we can accept, we expect an increase in referrals as we improve our status as a preferred provider |
| That's less than the 3% average merit market increase for the year, thus demonstrating our ability to control costs through productivity and optimization of staff |
| Continued progress with our people strategy remains a priority, and we believe we're winning the battle for labor |
| So we were pleased to see year-over-year that our applicant pool was up over 21% |
| And then again, we had another successful quarter with those full-time net new hires |
| We continually analyze our hospice business and effort to increase efficiency in the referral to-admission process and improve our ability to respond quickly to our referral sources |
| So we feel we're in a much better position |
| Our home health business development and branch operations teams continue to be successful in moving volume to our payer innovation agreements |
| For volumes, we expect the success we've had with our payer innovation team and our recruitment and retention of clinical staff to drive volume growth |
| We expect our Medicare pricing to increase approximately 1.2% in 2024 based on the home health final rule, and we expect our Medicare Advantage pricing to improve based on the success of our payer innovation team, including a full year of impact from the national agreement that became effective May 1, 2023 and the additional benefit of the new national agreement that became effective on January 1 of this year |
| Given our success with nursing hires, we are now able to turn some talent acquisition resources through recruiting additional therapists as our improved nursing workforce is allowing us to grow and add therapy team members |
| I think one of the things that we're excited about in 2024 is given the success we've had with the recruitment and retention of our clinical staff, when you have more staff, you're able to manage through some of those summer anomalies around paid time off and vacations and such |
| We had another strong quarter negotiating a total of 11 new agreements, with 8 of those negotiated at episodic rates |
| Persistent focus on our company strategies drove our positive fourth quarter results |
| This quality is a solution to the challenge of rising health care costs and helping payers manage their MLRs, helping to control emergency room visits, hospitalizations and readmissions results in higher patient and family satisfaction and control of health care dollars |
| So that was really good to see |
| The de novos that we opened up in 2022 and 2023 are doing well |
| So it really has given us, I think, an advantage sitting at the table with these payers |
| We anticipate our home health and hospice quality will continue to drive our future growth as well as employee retention |
| Since the inception of the payer innovation team in the summer of 2022, we have successfully negotiated 59 new agreements |
| For our hospice segment, we are focused on growing census, which will also allow us to gain operating leverage against the fixed cost structure associated with the management staffing model |
| Statement |
|---|
| Consolidated net revenue was $260.6 million for the fourth quarter, down $2.6 million or 1% year-over-year |
| But then so the Medicare revenue was down 14% for the year and, I guess, 16% in this quarter, year-over-year and down 7% sequentially |
| Admissions decreased 1.5% year-over-year, while average daily census decreased 4.3% year-over-year |
| Adjusted EBITDA was $25.2 million, down $5.1 million or 16.8% year-over-year |
| Our visits per episode in quarter 4 was flat year-over-year at 14.3% and down sequentially from quarter 3 to 14.9% |
| With our traditional Medicare mix of home health revenue now in line with peers, we expect the continued decline in our traditional Medicare volumes to slow at a rate consistent with the industry in 2024 |
| So like the non-episodic average, 43% below the average for the episodic volumes |
| On the cost side of the equation, we faced 2 primary headwinds in 2024: wage inflation and increased costs associated with durable medical equipment |
| Is that what you're trying to do to kind of give us more visibility? But I'm still surprised that, that average is still down much lower |
| A 3% average merit market increase resulted in an approximate $10 million net headwind for our company year-over-year |
| Our home office general and administrative expenses increased $4.3 million year-over-year to 10.3% of consolidated revenue, primarily due to a declining revenue base, investments in information technology and talent acquisitions and annual merit increases |
| Episodic admissions are beginning to stabilize as our sequential episodic admissions were down only 0.8% in the fourth quarter compared to the third quarter |
| So I guess the question is why Enhabit is losing market share? Crissy Carlisle Joanna, I don't think we're losing market share |
| As we've noted previously, our greatest challenge in forecasting relates to the shift of Medicare eligibles into Medicare Advantage and forecasting not only the mix of traditional Medicare admissions versus Medicare Advantage admissions but also forecasting the shift of Medicare Advantage admissions into our payer innovation contracts |
| We're not saying that Medicare is not going to continue to decline |
| So we did not aggressively pursue that volume in the past |
| This increase is primarily due to service issues we encountered with our durable medical equipment provider in the fourth quarter of 2023 |
| They continue to choose Medicare eligible -- continue to choose Medicare Advantage plans, where we're saying we shouldn't have those same double-digit declines that you've seen for us because we made that shift over 12 to 18 months |
| It sounds like you're obviously expecting that to moderate, and I would expect that, too |
| So their drop in the traditional Medicare wasn't like the Enhabit clip, as I referred to it over the past year |
Please consider a small donation if you think this website provides you with relevant information